Cargando…

Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities

Aberrant metabolism is arising interest in the scientific community not only because of the role it plays in the development and establishment of the tumor mass but also the possibility of drug poisoning of key enzymes overexpressed in tumor cells. Moreover, tumor metabolism provides key molecules t...

Descripción completa

Detalles Bibliográficos
Autores principales: Coronel-Hernández, Jossimar, Pérez-Yépez, Eloy Andrés, Delgado-Waldo, Izamary, Contreras-Romero, Carlos, Jacobo-Herrera, Nadia, Cantú-De León, David, Pérez-Plasencia, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531643/
https://www.ncbi.nlm.nih.gov/pubmed/34692471
http://dx.doi.org/10.3389/fonc.2021.676562
_version_ 1784586905851002880
author Coronel-Hernández, Jossimar
Pérez-Yépez, Eloy Andrés
Delgado-Waldo, Izamary
Contreras-Romero, Carlos
Jacobo-Herrera, Nadia
Cantú-De León, David
Pérez-Plasencia, Carlos
author_facet Coronel-Hernández, Jossimar
Pérez-Yépez, Eloy Andrés
Delgado-Waldo, Izamary
Contreras-Romero, Carlos
Jacobo-Herrera, Nadia
Cantú-De León, David
Pérez-Plasencia, Carlos
author_sort Coronel-Hernández, Jossimar
collection PubMed
description Aberrant metabolism is arising interest in the scientific community not only because of the role it plays in the development and establishment of the tumor mass but also the possibility of drug poisoning of key enzymes overexpressed in tumor cells. Moreover, tumor metabolism provides key molecules to maintain the epigenetic changes that are also an undisputed characteristic of each tumor type. This metabolic change includes the Warburg effect and alterations in key pathways involved in glutaminolysis, pentose phosphate, and unsaturated fatty acid biosynthesis. Modifications in all these pathways have consequences that impact genetics and epigenetics processes such as DNA methylation patterns, histone post-translational modifications, triggering oncogenes activation, and loss in tumor suppressor gene expression to lead the tumor establishment. In this review, we describe the metabolic rearrangement and its association with epigenetic regulation in breast cancer, as well as its implication in biological processes involved in cancer progression. A better understanding of these processes could help to find new targets for the diagnosis, prognosis, and treatment of this human health problem.
format Online
Article
Text
id pubmed-8531643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85316432021-10-23 Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities Coronel-Hernández, Jossimar Pérez-Yépez, Eloy Andrés Delgado-Waldo, Izamary Contreras-Romero, Carlos Jacobo-Herrera, Nadia Cantú-De León, David Pérez-Plasencia, Carlos Front Oncol Oncology Aberrant metabolism is arising interest in the scientific community not only because of the role it plays in the development and establishment of the tumor mass but also the possibility of drug poisoning of key enzymes overexpressed in tumor cells. Moreover, tumor metabolism provides key molecules to maintain the epigenetic changes that are also an undisputed characteristic of each tumor type. This metabolic change includes the Warburg effect and alterations in key pathways involved in glutaminolysis, pentose phosphate, and unsaturated fatty acid biosynthesis. Modifications in all these pathways have consequences that impact genetics and epigenetics processes such as DNA methylation patterns, histone post-translational modifications, triggering oncogenes activation, and loss in tumor suppressor gene expression to lead the tumor establishment. In this review, we describe the metabolic rearrangement and its association with epigenetic regulation in breast cancer, as well as its implication in biological processes involved in cancer progression. A better understanding of these processes could help to find new targets for the diagnosis, prognosis, and treatment of this human health problem. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531643/ /pubmed/34692471 http://dx.doi.org/10.3389/fonc.2021.676562 Text en Copyright © 2021 Coronel-Hernández, Pérez-Yépez, Delgado-Waldo, Contreras-Romero, Jacobo-Herrera, Cantú-De León and Pérez-Plasencia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Coronel-Hernández, Jossimar
Pérez-Yépez, Eloy Andrés
Delgado-Waldo, Izamary
Contreras-Romero, Carlos
Jacobo-Herrera, Nadia
Cantú-De León, David
Pérez-Plasencia, Carlos
Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title_full Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title_fullStr Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title_full_unstemmed Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title_short Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
title_sort aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531643/
https://www.ncbi.nlm.nih.gov/pubmed/34692471
http://dx.doi.org/10.3389/fonc.2021.676562
work_keys_str_mv AT coronelhernandezjossimar aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT perezyepezeloyandres aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT delgadowaldoizamary aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT contrerasromerocarlos aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT jacoboherreranadia aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT cantudeleondavid aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities
AT perezplasenciacarlos aberrantmetabolismasinductorofepigeneticchangesinbreastcancertherapeuticopportunities